ArticleHepatology international2026
New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCoagulation pathways are increasingly recognized as an influencer of tumor development. Experimental evidence suggests that commonly used anticoagulants, including warfarin and non-vitamin K oral anticoagulants (NOACs), may exhibit anti-tumor effects.
objectivesTo examine the association between NOAC use and the risk of hepatocellular carcinoma (HCC) among patients with chronic liver diseases due to hepatitis B virus (HBV), hepatitis C virus (HCV) or alcoholic liver disease (ALD).
designRetrospective population-based cohort study.
settingTaiwan National Health Insurance Research Database, 2012-2021.
participantsAdults with HBV, HCV, or ALD who initiated NOAC or warfarin therapy for at least 28 consecutive days and had no prior cancer diagnosis.
interventionsUse of rivaroxaban, dabigatran, apixaban, or edoxaban vs. warfarin. MEASUREMENTS: The primary outcome was new-onset HCC, ascertained via national catastrophic illness certification. Adjusted hazard ratios (aHRs) were estimated using Cox proportional hazards models with propensity score matching.
resultsAmong 29,332 matched patients, including 14,666 NOAC users and 14,666 warfarin users, NOAC use was associated with a significantly lower risk of HCC (aHR, 0.47; 95% CI 0.26-0.85; p = 0.013), which remained significant in the time-dependent model. The risk reduction was evident in patients with HCV infection and alcoholic liver disease, but not in those with HBV infection. Among individual NOACs, rivaroxaban and dabigatran were associated with a significantly lower risk of HCC. LIMITATIONS: Potential residual confounding; unavailable laboratory-based indicators of liver disease severity and viral activity; lack of dosage and adherence analyses.
conclusionsNOAC prescription was associated with a reduced risk of HCC compared with warfarin, although associations may vary across liver disease etiologies. Prospective studies are warranted to validate these findings.
Indexed as
Identifiers
42412361What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.